ReviewImmunologic research2013
Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus.
Review in Immunologic research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- The clinical significance of vitamin D in systemic lupus erythematosus: a systematic review.PloS one · 2013Pooled it
- Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.Arthritis research & therapy · 2022Trial
- Trial
- Salmonella infection and biofilms drive anti-C1q and anti-dsDNA autoantibodies in systemic autoimmunity.PLoS pathogens · 2026Article
- Advances and pitfalls in anti-double-stranded DNA autoantibody detection and interpretation.World journal of biological chemistry · 2026Review
- Genetic determinants of childhood onset systemic lupus erythematosus.Lupus science & medicine · 2026Article
- A Comprehensive Review of Thoracic Aortic Disease in Immunosuppressed States: Clinical Signals, Mechanisms, and Implications for Surveillance.Journal of cardiovascular development and disease · 2026Review
- Autoantibody repertoire in lupus nephritis: from pathogenic mechanisms to clinical integration for precision decision-making.Frontiers in immunology · 2026Review
- Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.Frontiers in immunology · 2026Article
- Lupus and IgA nephropathy: coexistence or coincident?Wiener klinische Wochenschrift · 2025Review
- Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights.Journal of clinical medicine · 2025Review
- Low complement items play different roles on the classification performance of SLICC-2012, EULAR/ACR-2019, and SLERPI.Frontiers in medicine · 2025Article
- Article
- The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Deep learning model to predict lupus nephritis renal flare based on dynamic multivariable time-series data.BMJ open · 2024Article
- Construction of competing endogenous RNA networks in systemic lupus erythematosus by integrated analysis.Frontiers in medicine · 2024Article
- Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review.Endocrine, metabolic & immune disorders drug targets · 2024Review
- B cell polygenic risk scores associate with anti-dsDNA antibodies and nephritis in systemic lupus erythematosus.Lupus science & medicine · 2023Article
- Article
- Osteopontin as a Biomarker in Chronic Kidney Disease.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic lupus erythematosus is a severe autoimmune disease that affects multiple organ systems resulting in diverse symptoms and outcomes. It is characterized by antibody production to a variety of self-antigens, but it is specifically associated with those against anti-dsDNA. Anti-dsDNA antibodies are present before the onset of clinical disease and are associated with severe manifestations of lupus such as glomerulonephritis. Their levels fluctuate with changes in disease activity and, in combination with the levels of complement proteins C3 and C4, are strong indicators of disease flare and treatment response in patients with lupus. The decreased complement levels that are noted during flares of lupus activity are believed to be secondary to increased autoantibody production and immune complex formation that results in tissue damage; however, recent data suggest that complement activation can also drive development of these pathogenic autoantibodies. This review will explore the various roles of complement in the development and pathogenesis of anti-dsDNA antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.